Key facts
- This page summarizes Moulder Leon O Jr.'s Form 4 filing for Zenas BioPharma, Inc. (ZBIO).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 17 Jun 2026, 18:02.
Moulder Leon O Jr. - 15 Jun 2026 Form 4 Insider Report for Zenas BioPharma, Inc. (ZBIO)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- ZBIO
- Reported as of
- 15 Jun 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Jun 2026, 18:02:59 UTC
- Prior SEC filing
- 18 May 2026
- Next SEC filing
- 22 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Jeffrey Held, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Moulder Leon O Jr. filed Form 4 for Zenas BioPharma, Inc. (ZBIO) on 17 Jun 2026.
Change
- Previous filing in this sequence was filed on 18 May 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001228865
Primary reporting owner
MOULDER LEON O JR
- Relationship
- Chief Executive Officer, Director
- Address
- C/O ZENAS BIOPHARMA, INC., 852 WINTER ST., SUITE 250, WALTHAM
- Signature
- By: /s/ Jeffrey Held, Attorney-in-Fact
- Signature date
- 17 Jun 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ZBIO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +500,000
- Change %
- Price
- $0.000000*
- Shares after
- 500,000
- Date
- 15 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 500,000
- Exercise price
- $18.71
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option vests as to 25% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.
SEC remarks
Chief Executive Officer